Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

FBRX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Forte Biosciences, Inc.NASDAQ: FBRX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 178.37M shares rose 1464.8% year over year, behind the +1552.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 21.2% from the prior quarter. Over 3 fiscal years it compounded at +496.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1464.8% toward the trailing-twelve-month pace of +1552.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
178.37M+21.2% QoQ
Last fiscal yearDec 2025
147.18M+4947.4% YoY
LTMMar 2026
88.77M+1552.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1464.8%——
1 year+4947.4%——
3-year CAGR+496.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
147.18M USD
Year-over-year change
+4947.4%
4-year CAGR
+302.9%

Weighted Avg Shares (Diluted) vs competitors

How FBRX compares with its peers on the latest reported figures

  • FBRX's LTM Mar 2026 weighted avg shares (diluted) of 88.77M shares is the 3rd highest of the 10 companies compared; the peer median is 37.49M shares.
  • Its year-over-year change of +1552.7% is the highest of 10, against a peer median of +12.5%.
  • Over three fiscal years its annual growth of +496.0% compares with a peer median of +15.3%.
FBRX Competitors Peer median
Weighted Avg Shares (Diluted) for FBRX and competitors
Company Period LTM YoY 3-year CAGR
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
FBRXForte Biosciences, Inc.LTM Mar 202688.77M +1552.7%+496.0%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +43.6%+15.3%
PEPGPepGen Inc.LTM Mar 202637.49M +15.0%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+3.9%
ACTUActuate Therapeutics IncLTM Mar 202621.96M +12.5%+11.8%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
Peer median (excluding FBRX) 37.49M+12.5%+15.3%

Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue36K09K39K64K
Gross Profit(36K)0(9K)(39K)(64K)
Gross Margin—————
Research & Development13.85M5.59M21.86M21.19M58.25M
Selling, General & Admin7.63M8.3M10.62M15.37M12.41M
Operating Expenses21.49M13.9M32.48M36.56M70.66M
Depreciation & Amortization36K36K9K39K64K
EBITDA(21.67M)(13.84M)(31.47M)(35.44M)(68.27M)
EBITDA Margin—————
Operating Income(21.49M)(13.9M)(32.49M)(36.6M)(70.66M)
Operating Margin—————
Interest Income001.12M1.31M2.72M
Interest Expense00000
Other Income / Expenses(222K)17K1.01M1.12M2.32M
Income Before Tax(21.71M)(13.88M)(31.48M)(35.48M)(68.34M)
Pre-Tax Margin—————
Income Tax Expense00001.04M
Net Income(21.71M)(13.86M)(31.48M)(35.48M)(69.38M)
Net Margin—————
EPS (Basic)(38.85)(19.96)(24.92)(12.17)(4.71)
EPS (Diluted)(38.85)(19.96)(24.92)(12.17)(4.71)
Weighted Avg Shares558.71K695.34K1.26M2.92M147.18M
Weighted Avg Shares (Diluted)558.71K695.34K1.26M2.92M147.18M

Forte Biosciences, Inc.

NASDAQ:FBRX

Intrinsic Alpha fair value

Locked

Current Price

$76.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.